Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 60.7% in August

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 216,000 shares, a decrease of 60.7% from the August 15th total of 549,900 shares. Currently, 0.4% of the shares of the stock are sold short. Based on an average trading volume of 187,100 shares, the short-interest ratio is currently 1.2 days.

Alzamend Neuro Stock Performance

Shares of ALZN opened at $0.22 on Friday. The firm has a market capitalization of $21.61 million, a price-to-earnings ratio of -1.32 and a beta of 0.01. The business’s fifty day moving average price is $0.37 and its two-hundred day moving average price is $0.49. Alzamend Neuro has a 52 week low of $0.21 and a 52 week high of $1.50.

Alzamend Neuro (NASDAQ:ALZN) last announced its quarterly earnings data on Wednesday, September 13th. The company reported ($0.04) EPS for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE bought a new position in shares of Alzamend Neuro in the 1st quarter worth $35,000. Geode Capital Management LLC boosted its position in shares of Alzamend Neuro by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 563,660 shares of the company’s stock worth $318,000 after purchasing an additional 37,910 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Alzamend Neuro in the 4th quarter worth $28,000. Charles Schwab Investment Management Inc. bought a new position in shares of Alzamend Neuro in the 4th quarter worth $30,000. Finally, HRT Financial LP bought a new position in shares of Alzamend Neuro in the 4th quarter worth $32,000. 6.37% of the stock is currently owned by institutional investors.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.